| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 553.84 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Chronic wounds, particularly those associated with diabetes, present an increasing public health burden due to their extended healing periods and high recurrence rates. One of the most common and clinically difficult forms of chronic wounds are diabetic foot ulcers, which are frequently distinguished by poor angiogenesis, ongoing inflammation, and wound environments that are rich in proteases. Over10 million people are impacted in Europe alone, with a high prevalence among those 65 and older. Over €4 billion is spent on healthcare each year, with each patient’s treatment costing between €6,000 and €10,000 [1,2]. Because of the ongoing inflammation and protease activity, conventional therapies frequently fail to promote complete regeneration, particularly in diabetic wound beds where heal-ing is severely compromised. As a result, there is now more interest in insulin, a biomolecule that is vital for wound heal-ing and has angiogenic, proliferative, and immunomodulatory qualities [2]. However, in chronic wound beds, insulin is extremely vulnerable to enzymatic degradation [3]. By encapsulating insulin in nanoparticles that resist degradation, enhance retention at the wound site, and permit con-trolled release, recent developments in nanomedicine overcome these drawbacks. These technologies better match drug availability with the changing wound environment and improve the regenerative effects of insulin [3,4]. As a result, combining topical insulin therapy with nanocarrier systems shows promise as a wound care approach, especially for diabetic ulcers and other chronic conditions.
Descrição
Palavras-chave
Topical insulin Nanocarriers Wound healing Drug delivery Skin regeneration Wound Polymer Lipid
Contexto Educativo
Citação
Editora
Taylor and Francis Group
Licença CC
Sem licença CC